SEC Form 25-NSE filed by BioPlus Acquisition Corp.

10/6/23 4:03:10 PM ET

$BIOS

Blank Checks

Finance

Get the next $BIOS alert in real time by email

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

UNITED STATES

OMB APPROVAL

OMB Number:		3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:		1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

333-258028

Issuer:	BioPlus Acquisition Corp.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	260 Madison Avenue, Suite 800
	New York	NEW YORK	10016
Telephone number:				(212) 287-4092

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Class A Ordinary Shares, Warrant, and Units

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2023-10-06	By	Tara Petta		AVP
Date		Name		Title

¹	Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Get the next $BIOS alert in real time by email

SEC Form 25-NSE filed by BioPlus Acquisition Corp.

Chat with this insight

Recent Analyst Ratings for
$BIOS

$BIOS
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Bioplus Sponsor Llc

$BIOS
Press Releases

Fastest customizable press release news feed in the world

BioPlus Acquisition Corp. Announces Termination of Business Combination Agreement with Avertix Medical, Inc. and its Intention to Liquidate

Avertix and BIOS Acquisition Corporation Mutually Agree to Terminate Proposed Business Combination

Carbonhand is available for Veterans in the US

$BIOS
Financials

Live finance-specific insights

Purple Innovation Announces Cooperative Framework with Coliseum Capital

$BIOS
SEC Filings

SEC Form 15-12G filed by BioPlus Acquisition Corp.